Relationship between use of statins and breast cancer risk by solubility and for the most commonly used statin medications
| . | Controls (n = 877) . | Ductal cases (n = 891) . | Lobular cases (n = 1,036) . | ||
|---|---|---|---|---|---|
| . | N (%) . | N (%) . | OR (95% CI) . | N (%) . | OR (95% CI) . |
| Never use | 674 (76.9) | 664 (74.8) | 1.00 (reference) | 782 (75.6) | 1.00 (reference) |
| Hydrophilic statins | |||||
| Current use | 13 (1.5) | 18 (2.0) | 1.56 (0.75–3.24) | 21 (2.0) | 1.65 (0.81–3.38) |
| Lipophilic statins | |||||
| Current use | 157 (17.9) | 166 (18.7) | 1.13 (0.88–1.45) | 196 (18.9) | 1.21 (0.95–1.54) |
| 6 months–<5 years | 84 (9.6) | 76 (8.6) | 0.95 (0.68–1.33) | 104 (10.1) | 1.17 (0.86–1.61) |
| 5 yrs–<10 yrs | 44 (5) | 45 (5.1) | 1.09 (0.70–1.69) | 44 (4.3) | 0.96 (0.62–1.50) |
| ≥10 years | 28 (3.2) | 43 (4.8) | 1.74 (1.05–2.86) | 45 (4.4) | 1.68 (1.02–2.76) |
| Ptrend | P = 0.119 | P = 0.094 | |||
| Atorvastatin | |||||
| Current use | 77 (8.8) | 93 (10.5) | 1.34 (0.96–1.85) | 98 (9.5) | 1.25 (0.91–1.74) |
| 6 months–<5 years | 37 (4.2) | 47 (5.3) | 1.39 (0.88–2.17) | 56 (5.4) | 1.46 (0.94–2.25) |
| 5 yrs–<10 yrs | 28 (3.2) | 26 (2.9) | 1.01 (0.58–1.77) | 24 (2.3) | 0.85 (0.48–1.51) |
| ≥10 years | 12 (1.4) | 20 (2.3) | 1.97 (0.94–4.11) | 18 (1.7) | 1.55 (0.73–3.30) |
| Ptrend | P = 0.048 | P = 0.254 | |||
| Simvastatin | |||||
| Current use | 50 (5.7) | 49 (5.5) | 0.97 (0.64–1.48) | 57 (5.5) | 1.05 (0.70–1.57) |
| 6 months–<5 years | 30 (3.4) | 29 (3.3) | 0.93 (0.54–1.58) | 35 (3.4) | 1.03 (0.62–1.72) |
| 5 yrs–<10 yrs | 14 (1.6) | 12 (1.4) | 0.94 (0.42–2.07) | 13 (1.3) | 0.90 (0.41–1.96) |
| ≥10 years | 6 (0.7) | 8 (0.9) | 1.30 (0.44–3.85) | 9 (0.9) | 1.49 (0.52–4.28) |
| Ptrend | P = 0.729 | P = 0.681 | |||
| . | Controls (n = 877) . | Ductal cases (n = 891) . | Lobular cases (n = 1,036) . | ||
|---|---|---|---|---|---|
| . | N (%) . | N (%) . | OR (95% CI) . | N (%) . | OR (95% CI) . |
| Never use | 674 (76.9) | 664 (74.8) | 1.00 (reference) | 782 (75.6) | 1.00 (reference) |
| Hydrophilic statins | |||||
| Current use | 13 (1.5) | 18 (2.0) | 1.56 (0.75–3.24) | 21 (2.0) | 1.65 (0.81–3.38) |
| Lipophilic statins | |||||
| Current use | 157 (17.9) | 166 (18.7) | 1.13 (0.88–1.45) | 196 (18.9) | 1.21 (0.95–1.54) |
| 6 months–<5 years | 84 (9.6) | 76 (8.6) | 0.95 (0.68–1.33) | 104 (10.1) | 1.17 (0.86–1.61) |
| 5 yrs–<10 yrs | 44 (5) | 45 (5.1) | 1.09 (0.70–1.69) | 44 (4.3) | 0.96 (0.62–1.50) |
| ≥10 years | 28 (3.2) | 43 (4.8) | 1.74 (1.05–2.86) | 45 (4.4) | 1.68 (1.02–2.76) |
| Ptrend | P = 0.119 | P = 0.094 | |||
| Atorvastatin | |||||
| Current use | 77 (8.8) | 93 (10.5) | 1.34 (0.96–1.85) | 98 (9.5) | 1.25 (0.91–1.74) |
| 6 months–<5 years | 37 (4.2) | 47 (5.3) | 1.39 (0.88–2.17) | 56 (5.4) | 1.46 (0.94–2.25) |
| 5 yrs–<10 yrs | 28 (3.2) | 26 (2.9) | 1.01 (0.58–1.77) | 24 (2.3) | 0.85 (0.48–1.51) |
| ≥10 years | 12 (1.4) | 20 (2.3) | 1.97 (0.94–4.11) | 18 (1.7) | 1.55 (0.73–3.30) |
| Ptrend | P = 0.048 | P = 0.254 | |||
| Simvastatin | |||||
| Current use | 50 (5.7) | 49 (5.5) | 0.97 (0.64–1.48) | 57 (5.5) | 1.05 (0.70–1.57) |
| 6 months–<5 years | 30 (3.4) | 29 (3.3) | 0.93 (0.54–1.58) | 35 (3.4) | 1.03 (0.62–1.72) |
| 5 yrs–<10 yrs | 14 (1.6) | 12 (1.4) | 0.94 (0.42–2.07) | 13 (1.3) | 0.90 (0.41–1.96) |
| ≥10 years | 6 (0.7) | 8 (0.9) | 1.30 (0.44–3.85) | 9 (0.9) | 1.49 (0.52–4.28) |
| Ptrend | P = 0.729 | P = 0.681 | |||
NOTE: OR adjusted for reference year, reference age, county of residence, and hormone therapy use. Bold values signify statistically significant estimates (P value <0.05).